Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Clarus Ventures Information
Clarus Ventures was acquired by
Blackstone Group.
The acquisition happend on 2018-10-04.
Details of the transaction were not public
Acquirer
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds which have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology companies with the deep and diverse expertise of the team in research and development, commercialization, business development and operations management at the global level. Clarus has $1.2 billion of assets under management across two lifesciences dedicated funds
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2012 | Oxford Immunotec | Equity | 28M |
| 9/2010 | TetraLogic Pharmaceuticals | Series C | 5M |
| 1/2013 | Avillion | Venture Round | - |
| 1/2007 | VBI Vaccines | Series A | 35.7M |
| 2/2016 | Forty Seven | Series A | 75M |
| 6/2016 | Flowonix | Debt Financing | 5M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 7/2008 | MacroGenics | Series D | 12.5M |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 7/2012 | SFJ Pharmaceuticals | Private Equity Round | 21M |
| 11/2014 | Flowonix | Venture Round | 20M |
| 7/2008 | Pearl Therapeutics | Series A | 18M |
| 11/2013 | Astria Therapeutics | Series B | 32.4M |
| 3/2012 | Sientra | Series C | 65M |
| 8/2016 | Cleave Therapeutics | Series B | 0 |
| 10/2013 | SFJ Pharmaceuticals | Venture Round | 30M |
| 10/2012 | SFJ Pharmaceuticals | Venture Round | 500k |
| 8/2010 | Taligen Therapeutics | Series B | 10M |
| 11/2011 | NanoString Technologies | Series D | 20M |
| 11/2011 | Cleave Therapeutics | Series A | 42M |
| 10/2007 | Oxford Immunotec | Series C | 0 |
| 2/2010 | Pearl Therapeutics | Series C | 15M |
| 5/2016 | GrayBug | Series B | 44.5M |
| 4/2010 | Lycera | Series A | 11M |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 3/2007 | Aerovance | Series C | 60M |
| 1/2008 | Taligen Therapeutics | Series B | 65M |
| 12/2009 | IVERIC bio | Series B | 30M |
| 1/2008 | Zogenix | Series B | 18M |
| 8/2016 | Avrobio | Series A | 25M |
| 6/2009 | NanoString Technologies | Series C | 30M |
| 8/2006 | Zogenix | Series A | 60M |
| 2/2018 | Avrobio | Series B | 60M |
| 1/2010 | Neomend | Series D | 30M |
| 12/2011 | Astria Therapeutics | Series A | 8M |
| 4/2010 | Astria Therapeutics | Series A | 39M |
| 6/2016 | Annexon Biosciences | Series B | 44M |
| 8/2008 | ESBATech | Series B | 22M |
| 11/2009 | FerroKin Biosciences | Venture Round | 15M |
| 6/2010 | FerroKin Biosciences | Series B | 12M |
| 8/2010 | TetraLogic Pharmaceuticals | Series C | 0 |
| 8/2006 | ESBATech | Series B | 41M |
| 6/2013 | Heptares Therapeutics | Series B | 0 |
| 11/2009 | Virdante Pharmaceuticals | Series A | 30M |
| 10/2017 | Forty Seven | Series B | 75M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 10/2009 | Zogenix | Series B | 36M |
| 5/2013 | NanoString Technologies | Venture Round | 150k |
| 1/2016 | ESSA Pharma | Post-IPO Equity | 15M |
| 9/2008 | Link Medicine | Venture Round | 40M |
| 4/2016 | Lumos Pharma | Series B | 34M |
| 12/2014 | Annexon Biosciences | Series A | 34M |
| 5/2010 | Oxford Immunotec | Series D | 26M |
| 3/2011 | Aerie Pharmaceuticals | Series B | 41.4M |
| 2/2017 | PATH | Venture Round | 25M |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 11/2014 | Restoration Robotics | Series C | 45M |
| 4/2013 | SFJ Pharmaceuticals | Private Equity Round | 13M |
| 8/2010 | Achillion Pharmaceuticals | Post-IPO Equity | 50.1M |
| 12/2007 | Pelikan Technologies | Series F | 69M |
| 9/2007 | Pearl Therapeutics | Series A | 15.5M |
| 11/2012 | Pearl Therapeutics | Series D | 65M |
| 8/2007 | Globus Medical | Series E | 110M |
| 12/2010 | TYRX | Venture Round | 20M |
| 4/2013 | Pearl Therapeutics | Venture Round | 41.7M |
| 12/2012 | NanoString Technologies | Series E | 15.3M |
| 7/2010 | Zogenix | Venture Round | 0 |
| 2/2013 | Astria Therapeutics | Venture Round | 9M |
| 8/2011 | Restoration Robotics | Series C | 41M |
| 12/2010 | Astria Therapeutics | Series A | 14.5M |
| 2/2010 | NanoString Technologies | Venture Round | 15M |
| 6/2008 | CoMentis | Series D | 0 |
| 2/2007 | Proacta | Series B | 35M |
| 2/2009 | Heptares Therapeutics | Series A | 30M |
| 9/2006 | CoMentis | Series B | 50M |
| 3/2009 | SFJ Pharmaceuticals | Series A | 45M |
| 4/2007 | Sientra | Series B | 85M |
| 12/2006 | SARcode Bioscience | Venture Round | 29M |
| 10/2008 | Biolex Therapeutics | Series D | 0 |
| 7/2015 | Nuvelution Pharma | Venture Round | - |
| 4/2012 | SFJ Pharmaceuticals | Private Equity Round | 35M |
| 4/2009 | Aerovance | Venture Round | 38M |
| 7/2011 | SARcode Bioscience | Series B | 44M |
| 1/2007 | SARcode Bioscience | Series A | 25M |
| 1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
| 10/2012 | Pearl Therapeutics | Private Equity Round | 23.3M |
| 5/2009 | Lycera | Series A | 0 |
| 9/2018 | Galera Therapeutics | Series C | 0 |
| 2/2018 | Avrobio | Series B | 0 |
| 10/2017 | Forty Seven | Series B | 0 |
| 9/2017 | Gritstone Bio | Series B | 0 |
| 2/2017 | PATH | Venture Round | 0 |
| 8/2016 | Cleave Therapeutics | Series B | 0 |
| 8/2016 | Avrobio | Series A | 0 |
| 6/2016 | Annexon Biosciences | Series B | 0 |
| 6/2016 | Flowonix | Debt Financing | 0 |
| 5/2016 | GrayBug | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
